In May 2013, actress Angelina Jolie shocked the world by announcing she carried a BRCA1 gene mutation, placing her at high risk for breast cancer. This prompted her to undergo a preventive double mastectomy. Through her powerful New York Times op-ed, she sought to destigmatize the disease and champion proactive prevention. Researchers now credit this moment with sparking the "Angelina Jolie effect."
A study in the British Medical Journal by Harvard Medical School researchers analyzed the impact of Jolie's disclosure on women's health decisions. Within 15 days of her column, BRCA1 and BRCA2 genetic screenings jumped 64% compared to the prior period. Six months later, rates were still 37% higher than before the announcement. Mastectomy trends are mixed—some studies show increases, others do not.
One outcome is undeniable: Jolie's courage elevated breast cancer awareness and drove more women toward vital screenings.
